Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report issued on Sunday, Wall Street Zen reports.
Other research analysts have also recently issued research reports about the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and issued a $20.00 price target on shares of Enanta Pharmaceuticals in a research report on Wednesday, September 23rd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $19.00.
Read Our Latest Report on ENTA
Enanta Pharmaceuticals Stock Performance
Enanta Pharmaceuticals (NASDAQ:ENTA – Get Free Report) last issued its quarterly earnings data on Monday, August 10th. The biotechnology company reported ($0.67) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The company had revenue of $14.36 million for the quarter, compared to the consensus estimate of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. As a group, sell-side analysts forecast that Enanta Pharmaceuticals will post -2.36 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently bought and sold shares of the business. Jupiter Topco LLC purchased a new stake in shares of Enanta Pharmaceuticals during the 2nd quarter valued at $53,252,000. Janus Henderson Group PLC boosted its holdings in shares of Enanta Pharmaceuticals by 1.5% in the 1st quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after buying an additional 54,396 shares during the last quarter. BlackRock Inc. bought a new position in Enanta Pharmaceuticals during the second quarter valued at about $47,304,000. ADAR1 Capital Management LLC bought a new position in Enanta Pharmaceuticals during the second quarter valued at about $19,603,000. Finally, Spruce Street Capital LP bought a new position in Enanta Pharmaceuticals during the second quarter valued at about $15,873,698. Hedge funds and other institutional investors own 94.99% of the company’s stock.
Enanta Pharmaceuticals Company Profile
Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and liver diseases. The company’s research and development activities have included treatments for hepatitis B virus (HBV), respiratory syncytial virus (RSV), SARS-CoV-2 and other infectious diseases.
Enanta’s most notable commercial contribution is glecaprevir, a direct-acting antiviral developed in collaboration with AbbVie and included in the Mavyret and Maviret treatment for chronic hepatitis C virus (HCV) infection.
See Also
- Five stocks we like better than Enanta Pharmaceuticals
- Salesforce Just Got a Rare Double Upgrade—What Changed?
- OpenAI’s Revenue Scare Could Be a Big Opportunity for Investors
- China Still Dominates Rare Earths—These 3 U.S. Companies Could Benefit
- 3 REITs That May Win in a Higher Interest Rate Environment
Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
